DDInter648 DDInter1376
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Entrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Disopyramide
Entrectinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Entrectinib may lead to a major life threatening interaction when taken with Disopyramide
Entrectinib may lead to a major life threatening interaction when taken with Macimorelin